Subscribe
shutterstock_1821779429_rafapress
rafapress / Shutterstock.com
10 February 2022GenericsAlex Baldwin

Lupin and Sun settle Bromsite patent suit after ruling

Sun Pharmaceuticals and Lupin Pharmaceuticals have decided to settle a patent suit related to Sun’s Bromsite (bromfenac) eye drops, invalidating an opinion handed down by the US District Court for the District of New Jersey in September.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Galderma sues Lupin over Oracea generic
7 December 2021   Galderma Laboratories has sued Lupin Pharmaceuticals alleging that it plans to manufacture and sell a generic version of Oracea prior to the expiration of key patents.
Generics
NJ judge invalidates Sun patent in BromSite suit
5 October 2021   A New Jersey court has invalidated a Sun Pharmaceuticals patent related to its anti-inflammatory eye drops BromSite in an infringement suit against generic drug manufacturer Lupin Pharmaceuticals.
Big Pharma
Sun unit resolves antitrust lawsuit for $485m
24 March 2022   Sun Pharmaceuticals has agreed to pay $485 million to settle an antitrust lawsuit relating to a generic drug application filed by its subsidiary, Ranbaxy, ending years of litigation.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Generics
Galderma sues Lupin over Oracea generic
7 December 2021   Galderma Laboratories has sued Lupin Pharmaceuticals alleging that it plans to manufacture and sell a generic version of Oracea prior to the expiration of key patents.
Generics
NJ judge invalidates Sun patent in BromSite suit
5 October 2021   A New Jersey court has invalidated a Sun Pharmaceuticals patent related to its anti-inflammatory eye drops BromSite in an infringement suit against generic drug manufacturer Lupin Pharmaceuticals.
Big Pharma
Sun unit resolves antitrust lawsuit for $485m
24 March 2022   Sun Pharmaceuticals has agreed to pay $485 million to settle an antitrust lawsuit relating to a generic drug application filed by its subsidiary, Ranbaxy, ending years of litigation.

More on this story

Generics
Galderma sues Lupin over Oracea generic
7 December 2021   Galderma Laboratories has sued Lupin Pharmaceuticals alleging that it plans to manufacture and sell a generic version of Oracea prior to the expiration of key patents.
Generics
NJ judge invalidates Sun patent in BromSite suit
5 October 2021   A New Jersey court has invalidated a Sun Pharmaceuticals patent related to its anti-inflammatory eye drops BromSite in an infringement suit against generic drug manufacturer Lupin Pharmaceuticals.
Big Pharma
Sun unit resolves antitrust lawsuit for $485m
24 March 2022   Sun Pharmaceuticals has agreed to pay $485 million to settle an antitrust lawsuit relating to a generic drug application filed by its subsidiary, Ranbaxy, ending years of litigation.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?